Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 15/20 | 0.38 |
| ▸ | CTSK | P43235 | 12/20 | 0.38 |
| ▸ | CTSL | P07711 | 3/20 | 0.36 |
| ▸ | CTSB | P07858 | 3/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343494 | 1.00 | CTSS (0.38) | CTSSCTSKCTSLCTSBCTSD | |
| SCHEMBL21175428 | 0.85 | CTSS (0.39) | CTSSCTSKCTSLCTSBHDAC6 | |
| SCHEMBL21175429 | 0.85 | CTSS (0.39) | CTSSCTSKCTSLCTSBHDAC6 | |
| SCHEMBL16812742 | 0.84 | CTSK (0.37) | CTSSCTSKCTSLCTSBCTSD | |
| SCHEMBL6888470 | 0.81 | CTSS (0.36) | CTSSCTSKCTSLCTSBCTSD | |
| SCHEMBL18634785 | 0.81 | HDAC6 (0.33) | CTSSCTSKHDAC6 | |
| SCHEMBL5724032 | 0.79 | HDAC6 (0.34) | CTSSCTSKHDAC6 | |
| SCHEMBL28478854 | 0.78 | CTSS (0.33) | CTSSCTSKCTSLCTSB | |
| SCHEMBL3265048 | 0.78 | CTSK (0.37) | CTSSCTSKCTSLCTSBMAOB | |
| SCHEMBL16812743 | 0.78 | CTSS (0.38) | CTSSCTSKCTSLCTSBCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835422-B2 | Substituted imidazoheterocycle derivatives | CARA THERAPEUTICS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120015930-A1 | SUBSTITUTED IMIDAZOHETEROCYCLE DERIVATIVES | CARA THERAPEUTICS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015930-A1 | SUBSTITUTED IMIDAZOHETEROCYCLE DERIVATIVES | CNR1, CNR2, HRH1 | CTSS 1807/4885CTSK 1745/4885CTSL 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.